Regeneron Pharmaceuticals Inc (NASDAQ:REGN) major shareholder Sanofi sold 172,904 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
NASDAQ REGN opened at $285.06 on Thursday. The company has a 50-day simple moving average of $293.66 and a two-hundred day simple moving average of $330.47. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. Regeneron Pharmaceuticals Inc has a 12-month low of $271.57 and a 12-month high of $442.00. The firm has a market cap of $31.54 billion, a price-to-earnings ratio of 14.40, a PEG ratio of 1.29 and a beta of 1.13.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the business posted $5.45 earnings per share. The company’s revenue was up 20.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals Inc will post 19.22 earnings per share for the current fiscal year.
A number of research firms recently commented on REGN. Robert W. Baird raised Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 target price on the stock in a research note on Wednesday, August 7th. Credit Suisse Group reduced their target price on Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. JPMorgan Chase & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, June 21st. ValuEngine lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. Finally, Leerink Swann set a $453.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 11th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $398.25.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $151,443,000. Parnassus Investments CA boosted its holdings in shares of Regeneron Pharmaceuticals by 290.6% during the second quarter. Parnassus Investments CA now owns 625,000 shares of the biopharmaceutical company’s stock worth $195,625,000 after purchasing an additional 465,000 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 700.5% during the second quarter. Nuveen Asset Management LLC now owns 352,815 shares of the biopharmaceutical company’s stock worth $110,432,000 after purchasing an additional 308,740 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 190.2% during the second quarter. Prudential Financial Inc. now owns 227,517 shares of the biopharmaceutical company’s stock worth $71,213,000 after purchasing an additional 149,111 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 62.3% during the second quarter. Renaissance Technologies LLC now owns 337,962 shares of the biopharmaceutical company’s stock worth $105,782,000 after purchasing an additional 129,700 shares during the period. Institutional investors and hedge funds own 66.54% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: The basics of gap trading strategies
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.